Loading…
Employees: 146
Size Prime Medicine (PRME) is a United States Health Care company (Biotechnology) with a market value of $843M, the 2359th largest of 3,117 United States companies the cockpit tracks. Shares closed at $4.65 on 6 Nov 2026.
Performance Over six months the shares gained 44.9%, against -19.9% for the median peer and -1.1% for the United States market (cap-weighted) — 2nd highest of 19 in its peer set.
Growth Revenue fell 17.9% over the last twelve months (peer median +0.9%); the operating margin is -4,824.9% (peer median -25.3%).
Valuation It trades at 211.3× enterprise value to sales against a peer median of 7.6× (2nd most expensive of 18).
Short interest Short interest is 18.1% of the free float (15 Oct 2026).
Next results Next results expected around 10 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $4.07M | $4.63M | $2.98M | $0 | $0 |
| Revenue growth | — | +55% | — | — | — |
| Gross profit | -$3.33M | -$2.69M | -$3.15M | -$4.65M | -$12.0M |
| EBITDA | -$189M | -$201M | -$196M | -$187M | -$105M |
| Net income | -$188M | -$201M | -$196M | -$198M | -$122M |
| Free cash flow | -$157M | -$167M | -$130M | -$174M | -$148M |
| Capital expenditure | $797,000 | $4.53M | $7.29M | $8.72M | $16.1M |
| Total debt | $112M | $116M | $40.8M | $13.6M | $28.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PRME | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +29.9% | -7.0% | highest of 21 |
| 6-month return | +44.9% | -19.9% | 2nd highest of 19 |
| Distance from 52-week high | -21.3% | -43.9% | highest of 21 |
| Revenue growth (TTM) | -17.9% | +0.9% | 6th lowest of 17 |
| Operating margin | -4,824.9% | -25.3% | 3rd lowest of 18 |
| EV / Sales | 211.3× | 7.6× | 2nd most expensive of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Prime Medicine PRME | United States | $843M | +45% | -18% | -4,825% | 211.3× | n/a | n/a |
| Peptidream 4587.T | Japan | $856M | -10% | +1% | -25% | 6.6× | n/a | n/a |
| Syndax Pharmaceuticals SNDX | United States | $859M | -56% | +160% | -62% | 3.5× | n/a | n/a |
| MeiraGTx MGTX | United States | $864M | -8% | +948% | 46% | 2.1× | -9.9% | +39.2% |
| GNI 2160.T | Japan | $866M | -29% | +10% | -24% | 5.7× | n/a | n/a |
| Wuhan Keqian Biology 688526.SS | China | $814M | -19% | -22% | 20% | 4.7× | 8.8% | +2.4% |
| R&G PharmaStudies 301333.SZ | China | $803M | -12% | +21% | 11% | 3.9× | 20.1% | +11.8% |
| Anhui Wanbang Pharmaceutical Technology 301520.SZ | China | $803M | +91% | -15% | -8% | 17.9× | 48.8% | +14.7% |
| Oxford BioMedica OXB.L | United Kingdom | $892M | -14% | +16% | -18% | 4.3× | n/a | n/a |
| Beijing SL Pharmaceutical 002038.SZ | China | $793M | -21% | -4% | -119% | 7.6× | -12.3% | -10.9% |
| Monte Rosa Therapeutics GLUE | United States | $902M | -45% | -84% | -633% | 11.1× | n/a | n/a |
| Inventiva IVA.PA | France | $912M | -29% | -100% | -307,063% | 14,560.9× | n/a | n/a |
| Alphamab Oncology 9966.HK | Hong Kong | $777M | -39% | -32% | -38% | 8.2× | n/a | n/a |
| Shaanxi Micot Pharmaceutical Technology 2335.HK | Hong Kong | $777M | n/a | n/a | n/a | n/a | n/a | n/a |
| Odyssey Therapeutics ODTX | United States | $924M | n/a | -33% | -5,415% | 208.9× | n/a | n/a |
| Nanjing Leads Biolabs 9887.HK | Hong Kong | $927M | -54% | n/a | -108% | 26.5× | n/a | n/a |
| Frontier Biotechnologies 688221.SS | China | $746M | -37% | +153% | -20% | 13.1× | 43.2% | +21.5% |
| Jade Biosciences JBIO | United States | $958M | -42% | n/a | n/a | n/a | n/a | n/a |
| China Animal Husbandry Industry 600195.SS | China | $960M | -17% | +1% | 2% | 1.4× | 6.6% | +4.4% |
| Shouyao Holdings Beijing 688197.SS | China | $726M | -16% | +4,564% | -92% | 43.1× | n/a | n/a |
| Alto Neuroscience ANRO | United States | $987M | +4% | n/a | n/a | n/a | n/a | n/a |